Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study
European Journal of Neurology · 2025
DOI: 10.1111/ene.16558 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Fabian Föttinger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Multiple Sclerosis, Databases, Factual. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Austrian MS Research Society.
Abstract (Originalsprache)
Background and purpose Autoimmune screening panels (ASPs) are often ordered as a part of the diagnostic workup in people with suspected multiple sclerosis (MS). However, data on the significance of ASP seropositivity in MS are scarce. This study aimed to investigate whether routine implementation of ASPs is viable in MS diagnostic workup.
Methods
In this retrospective study, we included patients from the Vienna Multiple Sclerosis Database who were diagnosed with MS according to current McDonald criteria between 2014 and 2021 and had an ASP performed.
Results
We analyzed 212 patients (mean age at serology = 30.4 [SD = 8.5] years, 67% female). Red flag symptoms for presence of systemic autoimmune disease were reported by 5.6% of patients during initial evaluation (sicca syndrome [ n = 5], joint pain [ n = 4], dermatitis [ n = 4]). Complement levels (C3c and C4) were below the lower reference level in 26 of 134 (19.4%) and three of 134 (2.2%), respectively. Antinuclear antibodies (ANAs) were positive in 24 of 210 (11.4%), with 18 (8.6%), five (2.4%), and one (0.5%) having mildly, moderately, and strongly positive ANA titers. Extractable nuclear antibody subsets were positive in 10 of 211 (4.7%) patients. ASPs led to the diagnosis of mixed connective tissue disease ( n = 1), psoriatic arthritis ( n = 1), and Sjögren syndrome ( n = 2; positive predictive value [PPV] = 4.9%, negative predictive value [NPV] = 99.3%). Among patients presenting with red flag symptoms, ASPs had better overall test performance (PPV = 100%, NPV = 88.9%).
Conclusions
The rate of ASP seropositivity in MS is low and within the range of the general population. Performance of ASPs without clinical suspicion of systemic autoimmune disease seems unwarranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Fabian Föttinger, Paulus Rommer, Barbara Kornek, Stefan Macher, Tobias Zrzavy, Gabriel Bsteh
Förderung
- Austrian MS Research Society
Zitieren
APA
Föttinger, F., Krajnc, N., Riedl, K., Leutmezer, F., Ponleitner, M., Rommer, P., Kornek, B., Macher, S., Schmied, C., Zebenholzer, K., Zulehner, G., Zrzavy, T., Berger, T., & Bsteh, G. (2025). Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study. European Journal of Neurology. https://doi.org/10.1111/ene.16558
Vancouver
Föttinger F, Krajnc N, Riedl K, Leutmezer F, Ponleitner M, Rommer P, et al. Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study. European Journal of Neurology. 2025. doi:10.1111/ene.16558
BibTeX
@article{Fttinger2025,
author = {Föttinger, Fabian and Krajnc, Nik and Riedl, Katharina and Leutmezer, Fritz and Ponleitner, Markus and Rommer, Paulus and Kornek, Barbara and Macher, Stefan and Schmied, Christiane and Zebenholzer, Karin and Zulehner, Gudrun and Zrzavy, Tobias and Berger, Thomas and Bsteh, Gabriel},
title = {Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.16558}
}
EUVIMED